News

SEP has acquired a minority stake in Exco InTouch which will use the funds to drive its growth in the clinical technology sector, especially in the mobile patient

Galapagos will develop new candidate drugs against the targets. As per the agreement, Servier can exclusively license each small molecule program after the completion of pre-clinical development by

Russian government has signed the agreement on behalf of Volgograd State Medical University, which will work with NIPER on pharmaceutical research, pharmabiz.com reported. NIPER director Professor KK Bhutani

According to the company, Stopain provides temporary relief for minor pains, muscle aches and stiffness commonly associated with arthritis. The product will be available as Stopain Extra Strength

IB1001 is a recombinant factor IX (FIX) product, which helps prevent bleeding in individuals with hemophilia B. The MAA comprises the data from the clinical program for IB1001,

The program requires ClinicalRM to provide an infrastructure of personnel, materials, equipment, facilities, science, and technology that will sustain an acceptable level of medical research. The Omnibus III

VGX-100 is a human antibody that acts against the human VEGF-C protein and is used to treat glioblastoma and metastatic colorectal cancers. Circadian is also developing VGX-100 for

The Roche Center of Excellence will provide highly potent dosage forms for preclinical, phase 1 and 2 clinical studies. The17,000ft² facility is equipped with specialized equipment which are

Clindamycin treats serious infections caused by susceptible anaerobic bacteria, besides treating infections due to susceptible strains of streptococci, pneumococci, and staphylococci. The latex-free injection which is expected to